Shorts Action: Vistagen Therapeutics Incorporated (NASDAQ:VTGN) Stock Is Shorted More

November 21, 2016 - By Ellis Scott   ·   0 Comments

Shorts Action: Vistagen Therapeutics Incorporated (NASDAQ:VTGN) Stock Is Shorted More

The stock of Vistagen Therapeutics Incorporated (NASDAQ:VTGN) registered an increase of 303.92% in short interest. VTGN’s total short interest was 20,600 shares in November as published by FINRA. Its up 303.92% from 5,100 shares, reported previously. With 75,300 shares average volume, it will take short sellers 0 days to cover their VTGN’s short positions. The short interest to Vistagen Therapeutics Incorporated’s float is 0.4%. The stock decreased 0.79% or $0.03 on November 18, hitting $3.75. Vistagen Therapeutics Inc (NASDAQ:VTGN) has declined 53.07% since April 19, 2016 and is downtrending. It has underperformed by 56.93% the S&P500.

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $31.34 million. The Firm is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system . It currently has negative earnings. The Company’s lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA).

VTGN Company Profile

VistaGen Therapeutics, Inc., incorporated on October 6, 2005, is a clinical-stage biopharmaceutical company. The Firm is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The Company’s lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies.

More notable recent Vistagen Therapeutics Inc (NASDAQ:VTGN) news were published by: Prnewswire.com which released: “VistaGen Therapeutics Reports Second Quarter 2017 Financial Results and …” on November 14, 2016, also Prnewswire.com with their article: “VistaGen Therapeutics Appoints Mark A. McPartland Vice President of Corporate …” published on October 04, 2016, Prnewswire.com published: “VistaGen Therapeutics Appoints Pharmaceutical CNS Drug Development Executive …” on June 20, 2016. More interesting news about Vistagen Therapeutics Inc (NASDAQ:VTGN) were released by: Prnewswire.com and their article: “VistaGen Therapeutics Bolsters Clinical and Regulatory Advisory Board with …” published on March 22, 2016 as well as Seekingalpha.com‘s news article titled: “Buy Vistagen, Another Promising Company In The Novel Antidepressant Space.” with publication date: May 11, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ellis Scott


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>